Maximizing Net Proceeds on Sale
Presented By: Benchmark International / Nelson Mullins
Getting to the closing table in a sell-side deal is only half the battle — what you walk away with depends on decisions made long before that day comes. In this session, we'll pull back the curtain on the deal structures, terms, and tactics that quietly erode net proceeds — from earnouts and escrow holdbacks to working capital adjustments and tax treatment. Hear directly from advisors and sellers who have navigated these moments firsthand. Learn where value gets transferred, how to spot it early, and what sophisticated sellers do differently to protect their position from first conversation to final wire.
Moderator:
Partner
Nelson Mullins
Doug Starcher is the Managing Partner of the Orlando office of Nelson Mullins, an AmLaw 75 law firm. He is also head of the firm's Florida M&A team. Doug has spent his entire career counseling entrepreneurial business owners from start-up to exit.
Panelists:
Managing Partner
Benchmark International
Dara Shareef is a Managing Partner with Benchmark International, where he helps lead the firm’s sellside M&A advisory services. With extensive experience in deal execution, analysis, and strategic growth, Dara guides clients through complex transactions, ensuring optimal outcomes. His leadership and expertise helps drive Benchmark International’s success, helping businesses owners achieve their goals with personalized, results-driven solutions.
Former Owner & CEO
.decimal
Richard had an idea to solve some of the issues that the radiation therapy industry faced with patient positioning and custom blocks. He began .decimal, a medical device manufacturing business in the radiation therapy industry, on a third story apartment balcony with $1,500 of borrowed money. Thirty one years later, .decimal has 35 CNC milling machines and 50,000 square feet of manufacturing space. .decimal has also spun off several new startups, including:
ProKnow: a high impact, low cost software to reduce variability and improve patient care. Critical areas of need include contouring and treatment planning, neither of which are solved by new equipment. Our cloud-based platform provides the tools for objective assessment of practical skills, targeted education, and robust documentation to increase quality and build a competitive advantage. In addition, by utilizing our cloud expertise, we've developed a platform for big data analysis of large patient datasets.
The road has not always been easy, but absolutely worth it knowing that the company has served 60,000+ cancer patients with over 330,000 patient-specific devices ... and still counting.